The prognostic role of systemic inflammation in patients undergoing resection of colorectal liver metastases: C-reactive protein (CRP) is a strong negative prognostic biomarker

2016 ◽  
Vol 114 (7) ◽  
pp. 895-899 ◽  
Author(s):  
Anne Helene Køstner ◽  
Christian Kersten ◽  
Thyra Löwenmark ◽  
Karin A. Ydsten ◽  
Reetta Peltonen ◽  
...  
Keyword(s):  
Liver Metastases ◽  
Systemic Inflammation ◽  
Colorectal Liver Metastases ◽  
Prognostic Biomarker ◽  
C Reactive Protein ◽  
Prognostic Role ◽  
Reactive Protein

scholarly journals The role of systemic inflammation in heart failure

2021 ◽  
Vol 102 (4) ◽  
pp. 510-517
Author(s):  
E V Khazova ◽  
O V Bulashova
Keyword(s):  
Heart Failure ◽  
Cardiovascular Diseases ◽  
Systemic Inflammation ◽  
Left Ventricular ◽  
Left Ventricular Ejection ◽  
C Reactive Protein ◽  
Ventricular Ejection Fraction ◽  
Reactive Protein ◽  
Highly Sensitive

The discussion continues about the role of systemic inflammation in the pathogenesis of cardiovascular diseases of ischemic etiology. This article reviews the information on the role of C-reactive protein in patients with atherosclerosis and heart failure in risk stratification for adverse cardiovascular events, including assessment of factors affecting the basal level of highly sensitive C-reactive protein. Research data (MRFIT, MONICA) have demonstrated a relationship between an increased level of C-reactive protein and the development of coronary heart disease. An increase in the serum level of highly sensitive C-reactive protein is observed in arterial hypertension, dyslipidemia, type 2 diabetes mellitus and insulin resistance, which indicates the involvement of systemic inflammation in these disorders. Currently, the assessment of highly sensitive C-reactive protein is used to determine the risk of developing myocardial infarction and stroke. It has been proven that heart failure patients have a high level of highly sensitive C-reactive protein compared with patients without heart failure. The level of C-reactive protein is referred to as modifiable risk factors for cardiovascular diseases of ischemic origin, since lifestyle changes or taking drugs such as statins, non-steroidal anti-inflammatory drugs, glucocorticoids, etc. reduce the level of highly sensitive C-reactive protein. In patients with heart failure with different left ventricular ejection fraction values, it was found that the regression of the inflammatory response is accompanied by an improvement in prognosis, which confirms the hypothesis of inflammation as a response to stress, which has negative consequences for the cardiovascular system.

scholarly journals C-reactive protein as a predictor of prognosis following curative resection for colorectal liver metastases

2007 ◽  
Vol 96 (2) ◽  
pp. 222-225 ◽  
Author(s):  
V K H Wong ◽  
H Z Malik ◽  
Z Z R Hamady ◽  
A Al-Mukhtar ◽  
D Gomez ◽  
...  
Keyword(s):  
Liver Metastases ◽  
Colorectal Liver Metastases ◽  
Curative Resection ◽  
C Reactive Protein ◽  
Reactive Protein

scholarly journals Prognostic role of the pretreatment C-reactive protein/albumin ratio in gastric cancer

Medicine ◽  
2020 ◽  
Vol 99 (10) ◽  
pp. e19362
Author(s):  
Xuanxuan Yang ◽  
Xing Song ◽  
Luo Zhang ◽  
Changping Wu
Keyword(s):  
Gastric Cancer ◽  
C Reactive Protein ◽  
Prognostic Role ◽  
Albumin Ratio ◽  
Reactive Protein

Impact of the C-reactive protein to albumin ratio on long-term outcomes after hepatic resection for colorectal liver metastases

2017 ◽  
Vol 214 (4) ◽  
pp. 752-756 ◽  
Author(s):  
Koichiro Haruki ◽  
Hiroaki Shiba ◽  
Takashi Horiuchi ◽  
Taro Sakamoto ◽  
Takeshi Gocho ◽  
...  
Keyword(s):  
Liver Metastases ◽  
Hepatic Resection ◽  
Colorectal Liver Metastases ◽  
C Reactive Protein ◽  
Long Term Outcomes ◽  
Albumin Ratio ◽  
Reactive Protein

Prognostic Value of Serum Ferritin, Transferrin Saturation and C- Reactive Protein At Diagnosis In Myelodysplastic Syndrome Patients: Analysis of Patients From the MDS Piedmont Registry,

Blood ◽  
2011 ◽  
Vol 118 (21) ◽  
pp. 3807-3807 ◽  
Author(s):  
Emanuela Messa ◽  
Daniela Gioia ◽  
Claudia Bertassello ◽  
Gianni Ciccone ◽  
Andrea Evangelista ◽  
...  
Keyword(s):  
Oxidative Stress ◽  
Myelodysplastic Syndrome ◽  
Negative Impact ◽  
Transferrin Saturation ◽  
C Reactive Protein ◽  
Prognostic Role ◽  
Normal Range ◽  
Reactive Protein ◽  
Iron Parameters

Abstract Abstract 3807 Background: The prognostic role of serum ferritin (SF) evaluation at baseline in patients (pts) affected by myelodysplastic syndrome (MDS) is still controversial. In fact, increased SF mainly due to transfusion requirement during disease history has a clear negative impact on overall survival (OS) (Malcovati et al., 2006) and also on leukemic evolution (LE) (Sanz, ASH 2008, de Swart ASH 2010) while contrasting data about its role at baseline on OS has been published. Park and colleagues (ASH 2010) failed to identify a negative prognostic impact of SF higher than 300 ng/mL in a cohort of low risk untransfused MDS patients while data from the European LeukemiaNet MDS registry identified SF as an independent prognostic factor for OS and progression-free survival in low- and int-1 MDS (de Swart, Edimburgh 2011). SF can be a marker of iron overload but also of inflammation and little is known about the impact on survival of other iron parameters such as transferrin saturation (TS) or inflammation such as C reactive protein (CRP) in MDS pts at diagnosis. Aim: Aim of our study was to evaluate the prognostic role of iron parameters and inflammation at diagnosis in MDS patients analyzing data collected in the MDS Piedmont Registry. Materials and methods: 1360 patients enrolled in the MDS Piedmont Registry (1999–2010) were analyzed. Patients with information on OS and LE and available baseline SF (n=670), TS (n=299), CRP (n=287) were included in the analysis. Survival analysis was performed using Kaplan-Meier method. Patients were stratified according to a cut off value of 800 ng/mL for SF, 40% for TS and values within or higher the normal range (0,8 mg/dL) for CRP. In order to compare survival curves, log-rank test was used. Cumulative incidence of LE, according to SF, TS and CRP levels, was calculated accounting for death from any causes as a competing event. Results: In the population with SF baseline values, 3-years OS in pts with SF < 800 ng/mL was 80.7 (95%CI: 75.8–84.8) and in pts with SF >800 ng/mL was 66.1 (95%CI: 46.7–79.8) (p= 0,006). The result seems to be confirmed in the low risk MDS subgroup in toto (n=226) and considering only the untransfused pts (136 cases) (p=0,0073 and p=0,0038 respectively) but no statistically significance in OS of high risk pts (n=108) has been observed. In subjects with available data on TS, 3-years OS for pts with TS lower than 40% was 75.0 (95% CI: 64.2–83.0) while in pts higher than 40% was 72.1 (95%CI: 59.5–81.4) (p=0,1). Finally, in pts with CRP values 3-years OS was 80.8 (95%CI: 69.7–88.2) for patients < 0,8 mg/dL and 47.2 (95%CI: 34.5–58.9) for pts > 0,8 mg/dL. Also 3-year cumulative incidence of LE was higher in pts with SF > 800 ng/mL [35.8 (95%CI: 20.3–51.2) vs 18.5 (95%CI: 14.4–22.5); p=0,002 ] and in those with CPR > 0,8 mg/dL [35.3 (95%CI: 23.9–46.7) vs 12.7 (95%CI: 5.7–19.7); p<0,001]. In TS subgroups no difference was observed [13.5 (95%CI: 7.0–20.0) for TS<40% vs 20.8 (95%CI: 11.8–29.8) for TS>40%; p=0.172]. Conclusions: although the limits of missing data, our results suggest that high levels of SF and CRP above the normal range at baseline should have a prognostic role in MDS pts, while TS seems to have little impact on OS. Moreover SF and CRP seem to have both a negative impact on LE. Our data suggest a more important prognostic role of chronic inflammation parameters than iron overload or oxidative stress in MDS patients at diagnosis. Further prospective evaluation of more specific parameter of oxidative stress and inflammation need to be analyzed in order to confirm our preliminary observation. Disclosures: No relevant conflicts of interest to declare.

scholarly journals Prognostic role of C-reactive protein in prostate cancer: a systematic review and meta-analysis

2014 ◽  
Vol 16 (3) ◽  
pp. 467 ◽  
Author(s):  
Qing Xu ◽  
Yi-Jing Chen ◽  
Zhu-Qing Liu ◽  
Li Chu ◽  
Jue-Min Fang ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Systematic Review ◽  
Meta Analysis ◽  
C Reactive Protein ◽  
Prognostic Role ◽  
Reactive Protein
Sign in / Sign up

Export Citation Format

Share Document